Trial Outcomes & Findings for A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents (NCT NCT00808028)
NCT ID: NCT00808028
Last Updated: 2015-04-14
Results Overview
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
538 participants
Primary outcome timeframe
Before vaccination 1 up to 1 month after vaccination 2
Results posted on
2015-04-14
Participant Flow
Participant milestones
| Measure |
Control
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 60 Microgram (mcg)
Given on a 0, 2-, 6-month schedule in Stage 1
|
rLP2086 120 mcg
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 200 mcg
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
|---|---|---|---|---|
|
Stage 1 (6 Months)
STARTED
|
121
|
22
|
198
|
198
|
|
Stage 1 (6 Months)
COMPLETED
|
116
|
21
|
191
|
183
|
|
Stage 1 (6 Months)
NOT COMPLETED
|
5
|
1
|
7
|
15
|
|
Stage 2 (Followed up to 48 Months )
STARTED
|
80
|
0
|
170
|
151
|
|
Stage 2 (Followed up to 48 Months )
COMPLETED
|
69
|
0
|
141
|
128
|
|
Stage 2 (Followed up to 48 Months )
NOT COMPLETED
|
11
|
0
|
29
|
23
|
Reasons for withdrawal
| Measure |
Control
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 60 Microgram (mcg)
Given on a 0, 2-, 6-month schedule in Stage 1
|
rLP2086 120 mcg
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 200 mcg
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
|---|---|---|---|---|
|
Stage 1 (6 Months)
Withdrawal by Subject
|
3
|
0
|
2
|
5
|
|
Stage 1 (6 Months)
Other
|
1
|
0
|
2
|
4
|
|
Stage 1 (6 Months)
Parent/legal guardian request
|
0
|
1
|
1
|
3
|
|
Stage 1 (6 Months)
Adverse Event
|
0
|
0
|
1
|
2
|
|
Stage 1 (6 Months)
Lost to Follow-up
|
1
|
0
|
1
|
0
|
|
Stage 1 (6 Months)
Protocol Violation
|
0
|
0
|
0
|
1
|
|
Stage 2 (Followed up to 48 Months )
Withdrawal by Subject
|
6
|
0
|
9
|
11
|
|
Stage 2 (Followed up to 48 Months )
Protocol Violation
|
0
|
0
|
1
|
0
|
|
Stage 2 (Followed up to 48 Months )
Lost to Follow-up
|
2
|
0
|
8
|
7
|
|
Stage 2 (Followed up to 48 Months )
Failed to return
|
2
|
0
|
5
|
4
|
|
Stage 2 (Followed up to 48 Months )
Adverse Event
|
1
|
0
|
1
|
0
|
|
Stage 2 (Followed up to 48 Months )
Other
|
0
|
0
|
1
|
1
|
|
Stage 2 (Followed up to 48 Months )
Parent's or guardian request
|
0
|
0
|
2
|
0
|
|
Stage 2 (Followed up to 48 Months )
Death
|
0
|
0
|
1
|
0
|
|
Stage 2 (Followed up to 48 Months )
Non-compliance
|
0
|
0
|
1
|
0
|
Baseline Characteristics
A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents
Baseline characteristics by cohort
| Measure |
Control
n=121 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 60 mcg
n=22 Participants
Given on a 0, 2-, 6-month schedule in Stage 1.
|
rLP2086 120 mcg
n=198 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 200 mcg
n=198 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
Total
n=539 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
13.8 Years
STANDARD_DEVIATION 2.05 • n=5 Participants
|
13.3 Years
STANDARD_DEVIATION 1.84 • n=7 Participants
|
14.3 Years
STANDARD_DEVIATION 2.11 • n=5 Participants
|
14.0 Years
STANDARD_DEVIATION 2.01 • n=4 Participants
|
14.0 Years
STANDARD_DEVIATION 2.05 • n=21 Participants
|
|
Sex: Female, Male
Female
|
61 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
113 Participants
n=5 Participants
|
103 Participants
n=4 Participants
|
288 Participants
n=21 Participants
|
|
Sex: Female, Male
Male
|
60 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
85 Participants
n=5 Participants
|
95 Participants
n=4 Participants
|
251 Participants
n=21 Participants
|
PRIMARY outcome
Timeframe: Before vaccination 1 up to 1 month after vaccination 2Population: mITT population included all randomized participants who received at least 1 vaccination and had at least 1 valid and determinate assay result. Here, 'N' signifies those participants who were evaluable for this measure during specified time period.
Outcome measures
| Measure |
rLP2086 120 mcg- Stage 2
n=22 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 2
n=195 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
Control-Stage 1
n=119 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 1
n=192 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
|---|---|---|---|---|
|
Percentage of Participants With at Least 4-fold Rise in Recombinant Lipoprotein 2086 (rLP2086) Specific Serum Bactericidal Assay Using Human Complement (hSBA) Titer: Before Vaccination 1 up to 1 Month After Vaccination 2
Subfamily A Strain A05 (N= 80, 18, 115, 106)
|
88.9 Percentage of participants
|
83.5 Percentage of participants
|
1.3 Percentage of participants
|
87.7 Percentage of participants
|
|
Percentage of Participants With at Least 4-fold Rise in Recombinant Lipoprotein 2086 (rLP2086) Specific Serum Bactericidal Assay Using Human Complement (hSBA) Titer: Before Vaccination 1 up to 1 Month After Vaccination 2
Subfamily B Strain B02 (N= 84, 21, 121, 114)
|
71.4 Percentage of participants
|
59.5 Percentage of participants
|
0.0 Percentage of participants
|
59.6 Percentage of participants
|
PRIMARY outcome
Timeframe: Before vaccination 1 up to 1 month after vaccination 3Population: mITT population included all randomized participants who received at least 1 vaccination and had at least 1 valid and determinate assay result. Here, 'N' signifies those participants who were evaluable for this measure during specified time period.
Outcome measures
| Measure |
rLP2086 120 mcg- Stage 2
n=22 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 2
n=195 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
Control-Stage 1
n=119 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 1
n=192 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
|---|---|---|---|---|
|
Percentage of Participants With at Least 4-fold Rise in Recombinant Lipoprotein 2086 (rLP2086) Specific Serum Bactericidal Assay Using Human Complement (hSBA) Titer: Before Vaccination 1 up to 1 Month After Vaccination 3
Subfamily A Strain A05 (N= 73, 19, 111,100)
|
89.5 Percentage of participants
|
92.8 Percentage of participants
|
5.5 Percentage of participants
|
94.0 Percentage of participants
|
|
Percentage of Participants With at Least 4-fold Rise in Recombinant Lipoprotein 2086 (rLP2086) Specific Serum Bactericidal Assay Using Human Complement (hSBA) Titer: Before Vaccination 1 up to 1 Month After Vaccination 3
Subfamily B Strain B02 (N= 79, 21, 112,105)
|
81.0 Percentage of participants
|
86.6 Percentage of participants
|
1.3 Percentage of participants
|
84.8 Percentage of participants
|
PRIMARY outcome
Timeframe: Vaccination 1 upto 1 Month after vaccination 3Population: Safety population included participants who received at least 1 dose of study vaccine.
Outcome measures
| Measure |
rLP2086 120 mcg- Stage 2
n=22 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 2
n=198 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
Control-Stage 1
n=121 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 1
n=195 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
|---|---|---|---|---|
|
Percentage of Participants With Atleast One Adverse Event (AE): Stage 1
Stage 1: Vaccination phase
|
81.8 Percentage of participants
|
38.9 Percentage of participants
|
44.6 Percentage of participants
|
47.2 Percentage of participants
|
|
Percentage of Participants With Atleast One Adverse Event (AE): Stage 1
Stage 1: 6-month follow up phase
|
18.2 Percentage of participants
|
1.5 Percentage of participants
|
4.1 Percentage of participants
|
2.6 Percentage of participants
|
PRIMARY outcome
Timeframe: 6 month after vaccination 3 up to 48 monthsPopulation: Safety population included participants who received at least 1 dose of study vaccine.
Outcome measures
| Measure |
rLP2086 120 mcg- Stage 2
n=170 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 2
n=151 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
Control-Stage 1
n=80 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 1
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
|---|---|---|---|---|
|
Percentage of Participants With Atleast One Adverse Event (AE): Stage 2
|
4.1 Percentage of participants
|
2.0 Percentage of participants
|
2.5 Percentage of participants
|
—
|
SECONDARY outcome
Timeframe: 1 month before vaccination 1, 1 month after vaccination 2, 3Population: mITT population included all randomized participants who received at least 1 vaccination and had at least 1 valid and determinate assay result. Here, 'N' signifies those participants who were evaluable for this measure during specified time period.
Outcome measures
| Measure |
rLP2086 120 mcg- Stage 2
n=22 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 2
n=195 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
Control-Stage 1
n=119 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 1
n=192 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
|---|---|---|---|---|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A04 Predose 1;1:32 (N= 64, 15, 90, 92)
|
0.0 Percentage of participants
|
10.0 Percentage of participants
|
10.9 Percentage of participants
|
12.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A04 Predose 1;1:64 (N= 64, 15, 90, 92)
|
0.0 Percentage of participants
|
7.8 Percentage of participants
|
3.1 Percentage of participants
|
5.4 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A04 Predose 1;1:128 (N= 64, 15, 90, 92)
|
0.0 Percentage of participants
|
1.1 Percentage of participants
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A04 1-month postdose 2;1:32 (N= 69, 21, 115, 115)
|
95.2 Percentage of participants
|
98.3 Percentage of participants
|
4.3 Percentage of participants
|
91.3 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 Predose 1;1:16 (N= 81, 21, 122, 114)
|
4.8 Percentage of participants
|
9.0 Percentage of participants
|
12.3 Percentage of participants
|
6.1 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 Predose 1;1:32 (N= 81, 21, 122, 114)
|
4.8 Percentage of participants
|
5.7 Percentage of participants
|
7.4 Percentage of participants
|
4.4 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 Predose 1;1:64 (N= 81, 21, 122, 114)
|
0.0 Percentage of participants
|
2.5 Percentage of participants
|
4.9 Percentage of participants
|
1.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 Predose 1;1:128 (N= 81, 21, 122, 114)
|
0.0 Percentage of participants
|
0.8 Percentage of participants
|
1.2 Percentage of participants
|
0.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 1-month postdose 2;1:16 (N= 83, 18, 118, 110)
|
88.9 Percentage of participants
|
89.0 Percentage of participants
|
7.2 Percentage of participants
|
90.9 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 1-month postdose 2;1:128 (N= 83, 18, 118, 110)
|
33.3 Percentage of participants
|
28.0 Percentage of participants
|
0.0 Percentage of participants
|
40.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 1-month postdose 3;1:16 (N= 76, 20, 114, 104)
|
90.0 Percentage of participants
|
96.5 Percentage of participants
|
11.8 Percentage of participants
|
96.2 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 1-month postdose 3;1:32 (N= 76, 20, 114, 104)
|
90.0 Percentage of participants
|
94.7 Percentage of participants
|
7.9 Percentage of participants
|
95.2 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 1-month postdose 3;1:128 (N= 76, 20, 114, 104)
|
40.0 Percentage of participants
|
68.4 Percentage of participants
|
1.3 Percentage of participants
|
60.6 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 Predose 1;1:128 (N= 80, 21, 119, 115)
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
1.3 Percentage of participants
|
0.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 1-month postdose 2;1:16 (N= 81, 20, 117, 107)
|
85.0 Percentage of participants
|
94.9 Percentage of participants
|
12.3 Percentage of participants
|
96.3 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 1-month postdose 2;1:32 (N= 81, 20, 117, 107)
|
85.0 Percentage of participants
|
90.6 Percentage of participants
|
11.1 Percentage of participants
|
88.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 1-month postdose 2;1:64 (N= 81, 20, 117, 107)
|
80.0 Percentage of participants
|
80.3 Percentage of participants
|
9.9 Percentage of participants
|
71.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 1-month postdose 2;1:128 (N= 81, 20, 117, 107)
|
45.0 Percentage of participants
|
39.3 Percentage of participants
|
2.5 Percentage of participants
|
45.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 1-month postdose 3 ;1:16 (N= 78, 21, 114, 112)
|
95.2 Percentage of participants
|
97.4 Percentage of participants
|
11.5 Percentage of participants
|
95.5 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 1-month postdose 3;1:128 (N= 78, 21, 114, 112)
|
61.9 Percentage of participants
|
74.6 Percentage of participants
|
2.6 Percentage of participants
|
67.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 postdose 1;1:16 (N= 84, 22, 124, 118)
|
0.0 Percentage of participants
|
1.6 Percentage of participants
|
3.6 Percentage of participants
|
2.5 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 postdose 1;1:32 (N= 84, 22, 124, 118)
|
0.0 Percentage of participants
|
0.8 Percentage of participants
|
1.2 Percentage of participants
|
1.7 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 postdose 1;1:64 (N= 84, 22, 124, 118)
|
0.0 Percentage of participants
|
0.8 Percentage of participants
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 1-month postdose 2 ;1:64 (N= 84, 21, 122, 114)
|
42.9 Percentage of participants
|
25.4 Percentage of participants
|
0.0 Percentage of participants
|
21.9 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 1-month postdose 2;1:128 (N= 84, 21, 122, 114)
|
14.3 Percentage of participants
|
7.4 Percentage of participants
|
0.0 Percentage of participants
|
8.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 1-month postdose 3 ;1:64 (N= 79, 21, 113, 105)
|
57.1 Percentage of participants
|
52.2 Percentage of participants
|
0.0 Percentage of participants
|
60.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 1-month postdose 3;1:128 (N= 79, 21, 113, 105)
|
42.9 Percentage of participants
|
19.5 Percentage of participants
|
0.0 Percentage of participants
|
19.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 Predose 1;1:16 (N= 83, 22, 118, 117)
|
0.0 Percentage of participants
|
2.5 Percentage of participants
|
2.4 Percentage of participants
|
2.6 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 Predose 1;1:64 (N= 83, 22, 118, 117)
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
1.2 Percentage of participants
|
0.9 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 1-month postdose 2;1:16 (N= 84, 19, 102, 96)
|
21.1 Percentage of participants
|
32.4 Percentage of participants
|
2.4 Percentage of participants
|
30.2 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 1-month postdose 3;1:16 (N= 68, 15, 86, 81)
|
53.3 Percentage of participants
|
75.6 Percentage of participants
|
5.9 Percentage of participants
|
67.9 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 1-month postdose 3;1:32 (N= 68, 15, 86, 81)
|
53.3 Percentage of participants
|
75.6 Percentage of participants
|
4.4 Percentage of participants
|
66.7 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 1-month postdose 3;1:64 (N= 68, 15, 86, 81)
|
46.7 Percentage of participants
|
60.5 Percentage of participants
|
1.5 Percentage of participants
|
58.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 1-month postdose 3;1:128 (N= 68, 15, 86, 81)
|
26.7 Percentage of participants
|
27.9 Percentage of participants
|
0.0 Percentage of participants
|
24.7 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 Predose 1 ;1:64 (N= 81, 22, 120, 116)
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
0.9 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 Predose 1 ;1:128 (N= 81, 22, 120, 116)
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
0.9 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 2;1:8 (n= 81, 21, 115, 106)
|
61.9 Percentage of participants
|
68.7 Percentage of participants
|
1.2 Percentage of participants
|
70.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 2;1:16 (N= 81, 21, 115, 106)
|
61.9 Percentage of participants
|
60.9 Percentage of participants
|
0.0 Percentage of participants
|
64.2 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 2;1:32 (N= 81, 21, 115, 106)
|
47.6 Percentage of participants
|
43.5 Percentage of participants
|
0.0 Percentage of participants
|
42.5 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 2;1:64 (N= 81, 21, 115, 106)
|
23.8 Percentage of participants
|
22.6 Percentage of participants
|
0.0 Percentage of participants
|
25.5 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 2;1:128 (N= 81, 21, 115, 106)
|
0.0 Percentage of participants
|
6.1 Percentage of participants
|
0.0 Percentage of participants
|
11.3 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 3;1:8 (N= 83, 21, 115, 111)
|
76.2 Percentage of participants
|
88.7 Percentage of participants
|
4.8 Percentage of participants
|
86.5 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 3; 1:16 (N= 83, 21, 115, 111)
|
76.2 Percentage of participants
|
86.1 Percentage of participants
|
1.2 Percentage of participants
|
85.6 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 3;1:32 (N= 83, 21, 115, 111)
|
76.2 Percentage of participants
|
80.9 Percentage of participants
|
0.0 Percentage of participants
|
80.2 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 3;1:64 (N= 83, 21, 115, 111)
|
47.6 Percentage of participants
|
53.9 Percentage of participants
|
0.0 Percentage of participants
|
61.3 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 1-month postdose 3;1:128 (N= 83, 21, 115, 111)
|
9.5 Percentage of participants
|
22.6 Percentage of participants
|
0.0 Percentage of participants
|
19.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A04 1-month postdose 2;1:64 (N= 69, 21, 115, 115)
|
85.7 Percentage of participants
|
82.6 Percentage of participants
|
1.4 Percentage of participants
|
72.2 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A04 1-month postdose 2;1:128 (N= 69, 21, 115, 115)
|
52.4 Percentage of participants
|
44.3 Percentage of participants
|
1.4 Percentage of participants
|
42.6 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 1-month postdose 2;1:32 (N= 83, 18, 118, 110)
|
88.9 Percentage of participants
|
85.6 Percentage of participants
|
3.6 Percentage of participants
|
81.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 1-month postdose 2;1:64 (N= 83, 18, 118, 110)
|
83.3 Percentage of participants
|
59.3 Percentage of participants
|
1.2 Percentage of participants
|
64.5 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A05 1-month postdose 3;1:64 (N= 76, 20, 114, 104)
|
85.0 Percentage of participants
|
89.5 Percentage of participants
|
3.9 Percentage of participants
|
87.5 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 Predose 1;1:16 (N= 80, 21, 119, 115)
|
4.8 Percentage of participants
|
7.6 Percentage of participants
|
10.0 Percentage of participants
|
6.1 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 Predose 1;1:32 (N= 80, 21, 119, 115)
|
4.8 Percentage of participants
|
5.0 Percentage of participants
|
7.5 Percentage of participants
|
4.3 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 Predose 1;1:64 (N= 80, 21, 119, 115)
|
0.0 Percentage of participants
|
0.8 Percentage of participants
|
2.5 Percentage of participants
|
3.5 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 1-month postdose 3 ;1:32 (N= 78, 21, 114, 112)
|
85.7 Percentage of participants
|
93.9 Percentage of participants
|
9.0 Percentage of participants
|
93.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
A56 1-month postdose 3 ;1:64 (n= 78, 21, 114, 112)
|
71.4 Percentage of participants
|
91.2 Percentage of participants
|
3.8 Percentage of participants
|
84.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 postdose 1;1:128 (N= 84, 22, 124, 118)
|
0.0 Percentage of participants
|
0.8 Percentage of participants
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 1-month postdose 2 ;1:16 (N= 84, 21, 122, 114)
|
76.2 Percentage of participants
|
68.9 Percentage of participants
|
1.2 Percentage of participants
|
65.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 1-month postdose 2 ;1:32 (N= 84, 21, 122, 114)
|
57.1 Percentage of participants
|
45.9 Percentage of participants
|
0.0 Percentage of participants
|
48.2 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 1-month postdose 3 ;1:16 (N= 79, 21, 113, 105)
|
85.7 Percentage of participants
|
90.3 Percentage of participants
|
3.8 Percentage of participants
|
85.7 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B02 1-month postdose 3 ;1:32 (N= 79, 21, 113, 105)
|
81.0 Percentage of participants
|
78.8 Percentage of participants
|
1.3 Percentage of participants
|
79.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 Predose 1;1:32 (N= 83, 22, 118, 117)
|
0.0 Percentage of participants
|
2.5 Percentage of participants
|
2.4 Percentage of participants
|
2.6 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 Predose 1;1:128 (N= 83, 22, 118, 117)
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 1-month postdose 2;1:32 (N= 84, 19, 102, 96)
|
21.1 Percentage of participants
|
30.4 Percentage of participants
|
2.4 Percentage of participants
|
28.1 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 1-month postdose 2;1:64 (N= 84, 19, 102, 96)
|
5.3 Percentage of participants
|
22.5 Percentage of participants
|
1.2 Percentage of participants
|
19.8 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B03 1-month postdose 2;1:128 (N= 84, 19, 102, 96)
|
0.0 Percentage of participants
|
10.8 Percentage of participants
|
0.0 Percentage of participants
|
2.3 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 Predose 1 ;1:8 (N= 81, 22, 120, 116)
|
0.0 Percentage of participants
|
3.3 Percentage of participants
|
2.5 Percentage of participants
|
2.6 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 Predose 1 ;1:16 (N= 81, 22, 120, 116)
|
0.0 Percentage of participants
|
1.7 Percentage of participants
|
1.2 Percentage of participants
|
2.6 Percentage of participants
|
|
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal To (>=) Prespecified Titer Level
B44 Predose 1 ;1:32 (N= 81, 22, 120, 116)
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
0.0 Percentage of participants
|
1.7 Percentage of participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Before Vaccination 1, 1 month after vaccination 2, 1 month after vaccination 3Population: mITT population included all randomized participants who received at least 1 vaccination and had at least 1 valid and determinate assay result. Here, 'N' signifies those participants who were evaluable for this measure during specified time period.
Outcome measures
| Measure |
rLP2086 120 mcg- Stage 2
n=22 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 2
n=195 Participants
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 48 months in Stage 2.
|
Control-Stage 1
n=119 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
rLP2086 200 mcg- Stage 1
n=192 Participants
Given on a 0, 2-, 6-month schedule in Stage 1 and follow-up to 48 months in Stage 2.
|
|---|---|---|---|---|
|
Immunogloblulin G (IgG) Measured by Geometric Mean Titer (GMT) for Sub Family A and Sub Family B
Subfamily(Sf) A Predose 1(N=106,22,156,173)
|
4.3 Titer
Interval 1.6 to 11.7
|
7.2 Titer
Interval 5.3 to 9.8
|
3.6 Titer
Interval 2.6 to 5.1
|
4.9 Titer
Interval 3.8 to 6.4
|
|
Immunogloblulin G (IgG) Measured by Geometric Mean Titer (GMT) for Sub Family A and Sub Family B
Sf A 1-month postdose 2(N=104, 22,168,166)
|
984.6 Titer
Interval 663.8 to 1460.4
|
1115.5 Titer
Interval 962.8 to 1292.5
|
4.9 Titer
Interval 3.5 to 6.9
|
1285.8 Titer
Interval 1082.3 to 1527.7
|
|
Immunogloblulin G (IgG) Measured by Geometric Mean Titer (GMT) for Sub Family A and Sub Family B
Sf A 1-month postdose 3(N=98,20, 158,148)
|
3120.3 Titer
Interval 1959.5 to 4968.8
|
2289.5 Titer
Interval 1967.0 to 2664.9
|
5.8 Titer
Interval 3.9 to 8.5
|
2342.6 Titer
Interval 2003.9 to 2738.5
|
|
Immunogloblulin G (IgG) Measured by Geometric Mean Titer (GMT) for Sub Family A and Sub Family B
Sf B Predose 1(N= 106,22,155,172)
|
4.2 Titer
Interval 1.4 to 12.7
|
5.4 Titer
Interval 4.1 to 7.2
|
3.5 Titer
Interval 2.6 to 4.6
|
3.9 Titer
Interval 3.0 to 5.0
|
|
Immunogloblulin G (IgG) Measured by Geometric Mean Titer (GMT) for Sub Family A and Sub Family B
Sf B 1-month postdose 2(N=104, 22,168,166)
|
405.8 Titer
Interval 298.7 to 551.4
|
816.5 Titer
Interval 701.0 to 951.1
|
3.7 Titer
Interval 2.7 to 5.0
|
852.0 Titer
Interval 729.1 to 995.6
|
|
Immunogloblulin G (IgG) Measured by Geometric Mean Titer (GMT) for Sub Family A and Sub Family B
Sf B 1-month postdose 3(N=98,20,158,148)
|
3264.2 Titer
Interval 2502.3 to 4258.1
|
2246.8 Titer
Interval 1988.1 to 2539.2
|
4.1 Titer
Interval 2.9 to 5.7
|
2553.3 Titer
Interval 2256.0 to 2889.7
|
Adverse Events
Control- Stage 1
Serious events: 3 serious events
Other events: 54 other events
Deaths: 0 deaths
rLP2086 60 mcg- Stage 1
Serious events: 1 serious events
Other events: 18 other events
Deaths: 0 deaths
rLP2086 120 mcg- Stage 1
Serious events: 3 serious events
Other events: 75 other events
Deaths: 0 deaths
rLP2086 200 mcg- Stage 1
Serious events: 8 serious events
Other events: 91 other events
Deaths: 0 deaths
Control-Stage 1 Follow-up
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
rLP2086 60 mcg- Stage 1 Follow up
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
rLP2086 120 mcg- Stage 1 Follow up
Serious events: 1 serious events
Other events: 2 other events
Deaths: 0 deaths
rLP2086 200 mcg- Stage 1 Follow up
Serious events: 2 serious events
Other events: 4 other events
Deaths: 0 deaths
Control-Stage 2
Serious events: 1 serious events
Other events: 1 other events
Deaths: 0 deaths
rLP2086 120 mcg- Stage 2
Serious events: 6 serious events
Other events: 1 other events
Deaths: 0 deaths
rLP2086 200 mcg- Stage 2
Serious events: 3 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Control- Stage 1
n=121 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1
|
rLP2086 60 mcg- Stage 1
n=22 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1
|
rLP2086 120 mcg- Stage 1
n=198 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1
|
rLP2086 200 mcg- Stage 1
n=195 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1
|
Control-Stage 1 Follow-up
n=121 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1
|
rLP2086 60 mcg- Stage 1 Follow up
n=22 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1
|
rLP2086 120 mcg- Stage 1 Follow up
n=198 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1
|
rLP2086 200 mcg- Stage 1 Follow up
n=195 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1
|
Control-Stage 2
n=80 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1 and further up to 48 months in Stage 2
|
rLP2086 120 mcg- Stage 2
n=170 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1 and further up to 48 months in Stage 2
|
rLP2086 200 mcg- Stage 2
n=151 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1 and further up to 48 months in Stage 2
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Infections and infestations
Eczema impetiginous
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.59%
1/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Perirectal abscess
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.2%
1/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Pilonidal cyst
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.66%
1/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Tonsillitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.59%
1/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Tonsillitis streptococcal
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.66%
1/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Alcohol poisoning
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.59%
1/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Head injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.59%
1/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.66%
1/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.59%
1/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CNS germinoma
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.59%
1/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Psychiatric disorders
Depression
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.59%
1/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Sinusitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cerebellar tumour
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Blood and lymphatic system disorders
Lymphadenitis
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Immune system disorders
Anaphylactic reaction
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Appendicitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Mononucleosis syndrome
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Pneumonia
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Abdominal injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Concussion
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Forearm fracture
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Jaw fracture
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Nervous system disorders
Headache
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Reproductive system and breast disorders
Ovarian cyst
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Vascular disorders
Hypertension
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
Other adverse events
| Measure |
Control- Stage 1
n=121 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1
|
rLP2086 60 mcg- Stage 1
n=22 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1
|
rLP2086 120 mcg- Stage 1
n=198 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1
|
rLP2086 200 mcg- Stage 1
n=195 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1
|
Control-Stage 1 Follow-up
n=121 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1
|
rLP2086 60 mcg- Stage 1 Follow up
n=22 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1
|
rLP2086 120 mcg- Stage 1 Follow up
n=198 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1
|
rLP2086 200 mcg- Stage 1 Follow up
n=195 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1
|
Control-Stage 2
n=80 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1 and further up to 48 months in Stage 2
|
rLP2086 120 mcg- Stage 2
n=170 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1 and further up to 48 months in Stage 2
|
rLP2086 200 mcg- Stage 2
n=151 participants at risk
Given on a 0, 2-, 6-month schedule in Stage 1, were then followed up to 6 months in Stage 1 and further up to 48 months in Stage 2
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
General disorders
Injection site dermatitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Injection site erythema
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Injection site haematoma
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Injection site pallor
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Injection site paraesthesia
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Injection site pruritus
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Vaccination site pallor
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Vessel puncture site haematoma
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Immune system disorders
Allergy to animal
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Immune system disorders
Allergy to chemicals
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Otitis media
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Upper respiratory tract infection
|
16.5%
20/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
59.1%
13/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
14.1%
28/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
10.8%
21/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Urinary tract infection
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.5%
3/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Head injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Soft tissue injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Investigations
Blood iron decreased
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Congenital, familial and genetic disorders
Factor V Leiden mutation
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.59%
1/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Cardiac disorders
Palpitations
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Ear and labyrinth disorders
Ear pain
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Eye disorders
Conjunctivitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.5%
3/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Eye disorders
Eye inflammation
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Eye disorders
Eyelid cyst
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Eye disorders
Photophobia
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Abdominal pain
|
1.7%
2/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.5%
3/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.1%
4/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Glossodynia
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Dental caries
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Gingivitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Tooth impacted
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Toothache
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Gastrointestinal disorders
Vomiting
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Influenza like illness
|
3.3%
4/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.1%
4/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Injection site pain
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.5%
3/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Pyrexia
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Injection site swelling
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Chest pain
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
General disorders
Hypothermia
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Pharyngitis
|
4.1%
5/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.0%
4/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
5.1%
10/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Gastroenteritis
|
2.5%
3/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.5%
5/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.1%
4/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.0%
8/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.5%
3/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Bronchitis
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.5%
3/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.1%
4/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Respiratory tract infection
|
3.3%
4/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Rhinitis
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.0%
4/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Viral infection
|
1.7%
2/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
18.2%
4/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Ear infection
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Influenza
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Laryngitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Lower respiratory tract infection
|
2.5%
3/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Acute tonsillitis
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
H1N1 influenza
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Mumps
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Tonsillitis
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.5%
5/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
3.6%
7/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Respiratory tract infection viral
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Sinusitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Acarodermatitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Cellulitis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Gastritis viral
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Herpes simplex
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Impetigo
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Pertussis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Pneumonia
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Pulpitis dental
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Subcutaneous abscess
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Contusion
|
1.7%
2/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Arthropod bite
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Concussion
|
1.7%
2/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Joint sprain
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Whiplash injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Back injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Chemical burn of skin
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Foreign body
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Ligament injury
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Post concussion syndrome
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Post procedural haematoma
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Skeletal injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Arthropathy
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Costochondritis
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Muscle contracture
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Tendonitis
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Torticollis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Dermatitis allergic
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Scar
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Dermatitis atopic
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Hangnail
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Ingrowing nail
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Photosensitivity reaction
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibroma
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Nervous system disorders
Headache
|
6.6%
8/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
9.1%
2/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.5%
3/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Nervous system disorders
Syncope
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.1%
4/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Nervous system disorders
Migraine
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Nervous system disorders
Burning sensation mucosal
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Nervous system disorders
Presyncope
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Nervous system disorders
Tremor
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Psychiatric disorders
Abnormal behaviour
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Reproductive system and breast disorders
Dysmenorrhoea
|
1.7%
2/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Reproductive system and breast disorders
Penile discharge
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
3.3%
4/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
9.1%
2/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
2.1%
4/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
5.0%
6/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.5%
3/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Respiratory, thoracic and mediastinal disorders
Asthma exercise induced
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
2.5%
3/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
4.5%
1/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.0%
2/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
1.2%
1/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.83%
1/121 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/22 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/198 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.51%
1/195 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/80 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/170 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
0.00%
0/151 • AE reported from Vaccination 1 upto 48 months after vaccincation 3 and SAE reported from Vaccination 1 upto 48 months after vaccincation 3
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
- Publication restrictions are in place
Restriction type: OTHER